dc.contributor.author |
Bashshur, Ziad F. |
|
dc.contributor.author |
Schakal, Alex R. |
|
dc.contributor.author |
El-Mollayess, Georges M. |
|
dc.contributor.author |
Arafat, Samer |
|
dc.contributor.author |
Jaafar, Dalida |
|
dc.contributor.author |
Salti, Haytham I. |
|
dc.date.accessioned |
2022-11-01T12:29:30Z |
|
dc.date.available |
2022-11-01T12:29:30Z |
|
dc.date.copyright |
2011 |
en_US |
dc.date.issued |
2022-11-01 |
|
dc.identifier.issn |
0275-004X |
en_US |
dc.identifier.uri |
http://hdl.handle.net/10725/14185 |
|
dc.description.abstract |
Purpose:
To compare verteporfin photodynamic therapy combined with intravitreal ranibizumab (combination therapy) versus ranibizumab monotherapy for management of neovascular age-related macular degeneration.
Methods:
Thirty patients (40 eyes) with neovascular age-related macular degeneration were prospectively allocated to combination therapy or monotherapy. In monotherapy, the induction phase consisted of 3 consecutive monthly ranibizumab injections (0.5 mg), while the combination therapy had a single session of photodynamic therapy with intravitreal ranibizumab. Follow-up treatment for either group consisted only of additional as-needed ranibizumab injections. The main outcome measure was that a proportion of eyes losing <15 letters of visual acuity after 12 months.
Results:
Except for 1 eye in combination therapy, all eyes in both groups lost <15 letters of visual acuity. At 12 months, there was a mean gain of +12 letters and +3.2 letters for monotherapy and combination therapy, respectively (relative percent change of 32% vs. 7%, P = 0.03). Anatomical improvement was similar in both groups. After induction, the time until ranibizumab retreatment was longer for combination therapy (P = 0.002) while ranibizumab injections were required more frequently with monotherapy (P = 0.015).
Conclusion:
Ranibizumab monotherapy showed greater improvement in visual acuity versus combination therapy. However, combination therapy required fewer ranibizumab injections. Larger trials need to confirm the findings of this pilot study. |
en_US |
dc.language.iso |
en |
en_US |
dc.title |
Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration |
en_US |
dc.type |
Article |
en_US |
dc.description.version |
Published |
en_US |
dc.author.school |
SOM |
en_US |
dc.author.idnumber |
201805227 |
en_US |
dc.author.department |
N/A |
en_US |
dc.relation.journal |
RETINA, The Journal of Retinal and Vitreous Diseases |
en_US |
dc.journal.volume |
31 |
en_US |
dc.journal.issue |
4 |
en_US |
dc.article.pages |
636-644 |
en_US |
dc.identifier.doi |
https://doi.org/10.1097/IAE.0b013e3181fe54ab |
en_US |
dc.identifier.ctation |
Bashshur, Z. F., Schakal, A. R., El-Mollayess, G. M., Arafat, S., Jaafar, D., & Salti, H. I. (2011). Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration. Retina, 31(4), 636-644. |
en_US |
dc.author.email |
georges.elmollayess@lau.edu.lb |
en_US |
dc.identifier.tou |
http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php |
en_US |
dc.identifier.url |
https://journals.lww.com/retinajournal/fulltext/2011/04000/RANIBIZUMAB_MONOTHERAPY_VERSUS_SINGLE_SESSION.2.aspx?casa_token=mSj2BKpTRfIAAAAA:iCQEkhnTNgCgUy2-riXihlrYAJYEnSTm_k7VCZ1LkTypvjjJxedT-wFeN-oGo9Og4wPe1belgY-Kb3dmDneKaKs |
en_US |
dc.author.affiliation |
Lebanese American University |
en_US |